Insider Brief
- A Deep Knowledge Group study found that global competitiveness in AI-driven biotechnology, healthcare and longevity increasingly depends on a country’s ability to deploy AI safely within real-world medical and regulatory systems rather than research capability alone.
- The report ranked the United States, United Kingdom and China as the leading national ecosystems for AI in life sciences, while Boston, San Francisco and Hong Kong led the city-level rankings.
- The study identified healthcare data infrastructure, regulatory readiness, capital investment, clinical validation and interoperability between healthcare and biotech systems as major factors shaping AI adoption in medicine and drug discovery.
Artificial intelligence is moving from laboratory experiments into the core infrastructure of drug discovery, healthcare delivery and preventive medicine, according to a new global study from Deep Knowledge Group that argues the next competitive divide will not be who develops AI models, but who can deploy them safely and at scale in life sciences.
The report, titled Global Artificial Intelligence Competitiveness Index — Part 6: AI in BioTech, Healthcare and Longevity, examines how countries and innovation hubs are building the infrastructure needed to integrate AI into biotechnology, hospitals and longevity-focused health systems. The study indicates that life-science AI is entering a more mature phase in which regulatory systems, healthcare data networks, capital markets and clinical validation matter as much as algorithmic research.
According to the study, the United States ranked first overall with a score of 93.1, followed by the United Kingdom, China, Switzerland and Germany. Boston and San Francisco led the city-level rankings, while Hong Kong, London and New York rounded out the top five global hubs.
The rankings reflect a broader transformation that is underway across the healthcare economy. AI is no longer viewed simply as a software tool for automating office work or generating text. Instead, researchers and policymakers increasingly see it as a platform technology capable of reshaping pharmaceutical research, hospital operations, diagnostics, clinical decision-making and preventive health systems.
The study describes the convergence of several macro forces driving adoption. These include the rise of large AI foundation models, mounting economic pressure on healthcare systems, growing interest in AI-assisted drug discovery and rising regulatory focus on clinical safety and auditability. The report also identifies longevity and preventive health as emerging economic sectors rather than niche scientific fields.
The result is an industry landscape in which AI systems are being evaluated not only for technical capability, but for whether they can survive the practical demands of healthcare deployment.
From Research Tool to Clinical Infrastructure
The report divides life-science AI into three broad categories, namely, AI in biotechnology, AI in healthcare and AI in longevity science.
According to the study, AI in biotechnology focuses heavily on drug discovery, genomics, biomarker analysis and molecular design. AI systems are increasingly used to search through massive biological datasets to identify drug targets, predict molecular behavior and reduce the cost and time required for early-stage pharmaceutical research.
In healthcare systems, the focus is moving toward operational deployment. The report describes AI applications ranging from diagnostic imaging and treatment planning to hospital workflow management and predictive analytics. These systems are intended to help physicians interpret complex clinical data faster while improving patient management and administrative efficiency.
The longevity sector represents a third — and arguably the newest — category. Here, AI is being applied to aging research, preventive medicine and personalized health optimization. According to the report, researchers are increasingly using AI to identify biomarkers associated with aging, predict disease risk years before symptoms appear and develop interventions intended to extend healthy lifespan.
The study suggests that these three areas overlap but operate under different technical and regulatory pressures. Drug discovery systems require high-performance computing and access to biological datasets. Clinical AI systems must function inside heavily regulated healthcare environments. Longevity-focused AI applications face additional ethical and policy debates around access, fairness and preventive health management.
One of the report’s central themes is that countries cannot be judged solely on AI research output. Instead, competitiveness depends on whether AI systems can move from research settings into functioning biomedical infrastructure.
That distinction appears repeatedly throughout the report. Researchers differentiate between “Research AI,” “Clinical AI” and “Commercial Deployment AI,” adding that each stage requires different capabilities.
- Research AI focuses on scientific discovery and exploratory analysis.
- Clinical AI integrates into patient care systems and hospital environments.
- Commercial deployment AI represents systems that have moved through validation and regulation into large-scale market adoption.
The study suggests many countries remain strong in research but weak in deployment.
The Data Problem
One of the biggest barriers identified in the report is healthcare data fragmentation.
Unlike consumer internet platforms, life-science AI depends on highly sensitive biological and clinical information spread across hospitals, insurers, research labs and government systems. According to the report, healthcare and biotech organizations frequently store information in incompatible systems, creating “data silos” that limit AI deployment.
That problem becomes especially important in healthcare environments where AI systems must combine medical imaging, electronic health records, genomic data and clinical trial information.
According to the report, countries with interoperable healthcare systems and governed data-sharing frameworks hold a major competitive advantage because AI systems improve with scale and diversity of data inputs.
The challenge is not merely technical because healthcare data is also heavily regulated.
The study points to privacy laws such as HIPAA in the United States and GDPR in Europe as examples of regulatory structures that shape how AI systems can access and process patient information.
As a result, the report shows that life-science AI requires a different competitiveness framework than other sectors of artificial intelligence. Consumer AI products can often scale rapidly with limited oversight. Medical AI systems typically face years of validation, clinical testing and regulatory review before broad deployment.
That process significantly changes the economics of the industry.
Drug Discovery and the Capital Race
The report describes life-science AI as one of the most capital-intensive segments of the AI economy.
Unlike software startups that can launch products quickly, AI-driven biotech firms often face years of clinical trials, regulatory reviews and expensive scientific validation. The study points out that venture capital remains critical to supporting early-stage AI drug discovery companies, while government funding plays an important role in areas such as longevity science and regenerative medicine where commercial returns remain uncertain.
The economics of AI drug discovery have attracted increasing investor attention over the past several years.
Pharmaceutical companies and startups are using machine learning systems to model protein interactions, analyze genomic data and simulate molecular behavior. The hope is that AI can reduce failure rates in drug development by identifying promising candidates earlier in the process.
According to the study, high-performance computing systems are becoming essential infrastructure for these efforts. Many AI-driven biotech applications require enormous computational resources capable of processing large-scale biological simulations and deep-learning models.
The report also emphasizes the growing relationship between biotech innovation and healthcare systems. AI-assisted drug development only becomes economically valuable when therapies can move through regulatory approval and into clinical use. That requires coordination between biotech firms, hospitals, insurers and regulators.
The study describes this relationship as a “symbiotic cycle” in which healthcare systems generate data, biotech firms build new therapies and AI infrastructure connects the two.
Regulation Becomes Strategic
The report repeatedly returns to regulation as a strategic factor rather than a bureaucratic obstacle.
According to the study, countries that create adaptive regulatory systems for AI-driven medicine may gain significant competitive advantages. Regulators increasingly function as enablers of innovation by establishing trusted pathways for AI deployment in healthcare and biotech.
That issue is particularly important for AI systems involved in diagnosis or treatment recommendations. Errors or algorithmic bias in these systems can directly affect patient outcomes.
The study reports that transparency, auditability and clinical validation are becoming central requirements for deployment. AI systems that cannot explain decisions or demonstrate reliability in clinical environments may struggle to gain regulatory approval or physician trust.
The report also warns that life-science AI raises broader ethical concerns around equity, access and bias.
According to the study, AI systems used in longevity medicine or preventive healthcare could deepen inequality if advanced treatments remain accessible only to wealthy populations. Researchers also note concerns about algorithmic bias in diagnostic systems trained on limited demographic datasets.
The Geography of AI Life Sciences
The rankings themselves reveal the geographic concentration of AI life-science power.
The United States dominates due to the combination of major research universities, venture capital markets, hospital systems and pharmaceutical infrastructure. Boston and San Francisco, in particular, reflect the clustering effect created when biotech companies, AI firms, academic institutions and investors operate in close proximity.
China’s strong placement reflects its scale, government investment and rapidly expanding AI ecosystem, while Switzerland’s high ranking reflects the country’s pharmaceutical industry and biotech infrastructure.
The United Kingdom also performed strongly, particularly through hubs such as London, Cambridge and Oxford. Singapore emerged as one of the leading Asian centers for AI-enabled healthcare and biotech development.
The report shows that city-level ecosystems matter because biomedical innovation is often concentrated geographically. AI leadership in life sciences tends to emerge around tightly connected networks of hospitals, universities, investors and research centers rather than across entire nations uniformly.
Ultimately, according to the report, the countries that succeed over the next decade will likely be those capable of aligning scientific discovery, investment capital, healthcare infrastructure and regulation into coherent deployment systems. In life sciences, AI competitiveness increasingly depends less on building experimental models and more on building functioning ecosystems capable of turning those models into trusted medical infrastructure.
The complete report is available here.
